



A Continuing Medical Education Activity
The 18th Conference on
Retroviruses and Opportunistic Infections (CROI):
Online Expert Poster Review and Discussion


Jointly sponsored by the Postgraduate Institute for Medicine and ViralEd, LLC

**QDMRK, A Phase III Study of the Safety and Efficacy
of Once Daily (QD) Versus Twice Daily (BID)
Raltegravir (RAL) in Combination Therapy for
Treatment-Naïve HIV-Infected Patients (Pts)**


J. Eron, J. Rockstroh, J. Reynes, J. Andrade, J. Madruga, J. Zhao,
P. Sklar, B-Y. Nguyen for the QDMRK Study Team

**QDMRK: Comparison
of RAL QD and BID**

- Multicenter, double-blind, randomized, active-controlled study
- Non-inferiority design (10% margin)



QDMRK: HIV RNA < 50 copies/mL (NC=F)



Number of Contributing Patients

	0	4	8	12	16	24	36	48
◆ RAL 800 mg QD	382	382	377	381	379	380	381	382
■ RAL 400 mg BID	388	388	386	387	386	387	386	386

Eron J, et al. 18th CROI; Boston, MA; February 27-March 2, 2011. Abst. 150LB.

QDMRK: HIV RNA < 50 copies/mL at Week 48 by Subgroup (NC=F)

	Response				Difference
	RAL QD		RAL BID		% (95% CI)
	n/N	%	n/N	%	
Baseline HIV RNA (copies/mL)					
> 100,000 copies/mL	113/152	74.3	128/152	84.2	-9.9 (-19.0, -0.8)
≤ 100,000 copies/mL	205/230	89.1	215/234	91.9	-2.7 (-8.3, 2.7)
Baseline CD4 (cells/mm³)					
≤ 200 cells/mm ³	63/89	70.8	80/99	80.8	-10.0 (-22.3, 2.2)
> 200 cells/mm ³	254/292	87.0	262/286	91.6	-4.6 (-9.8, 0.4)

Eron J, et al. 18th CROI; Boston, MA; February 27-March 2, 2011. Abst. 150LB.

QDMRK: 48 Week Summary of Virologic Failures and Resistance

	Raltegravir QD	Raltegravir BID
Virologic Failures	53/382 (13.9%)	35/388 (9.0%)
VF >400 c/mL, (data available)	30 (27 with IN data)	16 (12 with IN data)
No Evidence of Resistance	7	7
Integrase Resistance and FTC Resistance	9	2
FTC Resistance Alone	11	4

Number of VF by Baseline HIV RNA

BL VL (cp/mL)	Raltegravir QD	Raltegravir BID
≤ 100,000	16	8
> 100,000	37	27

Definition Of Virologic Failure


- HIV RNA >50 copies/mL at Week 24 (confirmed at least 1 week apart),
- OR
- Virologic relapse after initial response: HIV RNA >50 copies/mL (on 2 consecutive measurements at least 1 week apart) after initial response with HIV RNA <50 copies/mL

Most Pts failed with 2 or more mutations known to be associated with RAL resistance. Signature mutations included N155H (4 pts in QD), Y143C/R (3 pts in QD, 1 pt in BID)

NOTE: No Patient in Either Arm Failed with Evidence of TDF Resistance

Eron J, et al. 18th CROI; Boston, MA; February 27-March 2, 2011. Abst. 150LB.

QDMRK: Histograms for GM C_{trough} and % with HIV RNA <50 copies/mL (Observed Failure)



Overall Responses:

400 mg BID - 92%

800 mg QD - 87%

In 800 mg QD dataset, there is a drop-off in efficacy for patients in lowest C_{trough} quartile

Eron J, et al. 18th CROI; Boston, MA; February 27-March 2, 2011. Abst. 150LB.